Rilonacept
| Clinical data | |
|---|---|
| Trade names | Arcalyst |
| Other names | IL-1 Trap |
| AHFS/Drugs.com | Monograph |
| License data |
|
Subcutaneous | |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C9030H13932N2400O2670S74 |
| Molar mass | 201209.36 g·mol−1 |
  (what is this?) (verify) | |
Rilonacept, sold under the brand name Arcalyst, is a
interleukin 1 inhibitor.[4]
Rilonacept is a dimeric
IL-1.[5]
Rilonacept was given an
familial cold autoinflammatory syndrome, Muckle–Wells syndrome.[3][6] Rilonacept is the first drug approved by the FDA to treat recurrent pericarditis.[3] Rilonacept was approved for medical use in the United States in February 2008.[7]
On May 8, 2012, an FDA Advisory Panel voted 11–0 against the approval of rilonacept for the treatment of gout, stating that the benefits did not outweigh the risks associated with the drug.[8]
References
- ^ a b "Arcalyst- rilonacept injection, powder, lyophilized, for solution". DailyMed. Retrieved 18 March 2021.
- ^ a b "Rilonacept Regeneron (previously Arcalyst) EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 18 March 2021.
- ^ a b c "FDA Approves First Treatment for Disease That Causes Recurrent Inflammation in Sac Surrounding Heart". U.S. Food and Drug Administration (FDA). 18 March 2021. Retrieved 18 March 2021.
This article incorporates text from this source, which is in the public domain.
- PMID 19635719.
- PMID 18560622.
- ^ "Arcalyst FDA Approval History - Drugs.com". Archived from the original on 2012-05-16. Retrieved 2012-05-08.
- ^ "Drug Approval Package: Arcalyst (Rilonacept) NDA #125249". U.S. Food and Drug Administration (FDA). 2 May 2008. Retrieved 20 March 2021.
- ^ "Medical News: FDA Panel Nixes Gout Drug - in Rheumatology, General Rheumatology from MedPage Today". 8 May 2012. Archived from the original on 2012-05-21. Retrieved 2012-05-08.
External links
- "Rilonacept". Drug Information Portal. U.S. National Library of Medicine.